{"id":"xtr006","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, XTR006 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"XTR006 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:00.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07115238","phase":"PHASE3","title":"Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2024-11-20","conditions":"Alzheimer Disease, Neurofibrillary Tangle","enrollment":354},{"nctId":"NCT06151808","phase":"NA","title":"Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects","status":"COMPLETED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-09-01","conditions":"Alzheimer Disease","enrollment":42},{"nctId":"NCT06151795","phase":"PHASE1","title":"A Study to Evaluate XTR006 in Chinese Volunteers","status":"COMPLETED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2023-06-12","conditions":"Alzheimer Disease","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["[18F]MK 6240","Florquinitau"],"phase":"phase_3","status":"active","brandName":"XTR006","genericName":"XTR006","companyName":"Sinotau Pharmaceutical Group","companyId":"sinotau-pharmaceutical-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XTR006 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}